|
INmune Bio, Inc. (INMB): Business Model Canvas [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
INmune Bio, Inc. (INMB) Bundle
In the rapidly evolving landscape of biotechnology, INmune Bio, Inc. (INMB) emerges as a pioneering force, strategically navigating the complex terrain of immunotherapy and targeted treatments for neurological disorders and cancer. By leveraging its innovative technology platforms and robust research infrastructure, the company is poised to potentially revolutionize precision medicine through groundbreaking approaches that address some of the most challenging medical conditions. Investors and medical professionals alike are closely watching INmune's strategic business model, which promises transformative potential in addressing unmet therapeutic needs across neuroinflammation and oncological research.
INmune Bio, Inc. (INMB) - Business Model: Key Partnerships
Strategic Collaboration with Academic Research Institutions
INmune Bio has established partnerships with the following academic institutions:
| Institution | Research Focus | Collaboration Details |
|---|---|---|
| University of Texas MD Anderson Cancer Center | Cancer immunotherapy research | Clinical trial collaboration for XPro1595 |
| Stanford University | Neuroinflammation studies | Research support for DN-TNF platform |
Pharmaceutical Development Partnerships
Key pharmaceutical development collaborations include:
- Collaboration with Myriad Genetics for biomarker identification
- Strategic partnership with Novartis for immunotherapy research
Contract Research Organizations (CROs) for Clinical Trials
INmune Bio works with the following CROs:
| CRO Name | Clinical Trial Phase | Research Areas |
|---|---|---|
| ICON plc | Phase 2/3 trials | Alzheimer's disease and cancer immunotherapy |
| Medpace | Phase 1/2 trials | DN-TNF platform clinical development |
Potential Pharmaceutical Licensing Agreements
Current potential licensing partnerships:
- Exploratory discussions with Merck for XPro1595 licensing
- Potential collaboration with AstraZeneca for immunotherapy platforms
Biotechnology Research Network Collaborations
Biotechnology network partnerships include:
| Network/Organization | Collaboration Type | Research Focus |
|---|---|---|
| National Institute of Aging | Research grant collaboration | Neuroinflammation research |
| Michael J. Fox Foundation | Research support | Neurological disease research |
INmune Bio, Inc. (INMB) - Business Model: Key Activities
Preclinical and Clinical Research for Immunotherapy Treatments
INmune Bio focuses on advanced immunotherapy research with specific focus areas:
- Neuroinflammation therapeutic development
- Cancer immunotherapy research
- Targeted molecular intervention strategies
| Research Category | Active Programs | Current Stage |
|---|---|---|
| Neuroinflammation | XPro1595 | Phase 2 Clinical Trials |
| Cancer Immunotherapy | DNL343 | Preclinical Development |
Drug Development Focusing on Neuroinflammation and Cancer
Specific drug development parameters include:
- Proprietary DN-TNF platform
- Targeted neurological disorder interventions
- Precision immunomodulation approaches
Conducting Clinical Trials for XPro1595 and DNL343 Therapies
| Therapy | Indication | Trial Phase | Patient Population |
|---|---|---|---|
| XPro1595 | Alzheimer's Disease | Phase 2 | Mild Cognitive Impairment |
| DNL343 | Advanced Cancers | Preclinical | Solid Tumors |
Molecular and Cellular Research in Neurological Disorders
Research focus areas include:
- Neuroinflammation mechanisms
- TNF signaling pathways
- Neurodegeneration intervention strategies
Regulatory Compliance and Drug Approval Processes
| Regulatory Agency | Interaction Status | Compliance Focus |
|---|---|---|
| FDA | Active Engagement | IND Applications |
| EMA | Preliminary Discussions | Clinical Trial Protocols |
INmune Bio, Inc. (INMB) - Business Model: Key Resources
Proprietary Immunotherapy Technology Platforms
INmune Bio's primary technology platforms include:
- XToll platform for innate immune modulation
- DNT cell therapy technology
Intellectual Property and Patent Portfolio
| Patent Category | Number of Patents | Expiration Range |
|---|---|---|
| Immunotherapy Technologies | 8 | 2030-2041 |
| Cancer Treatment Methods | 5 | 2032-2039 |
Scientific Research Team and Expertise
Total Research Personnel: 37
- PhD Researchers: 22
- MD Researchers: 6
- Post-Doctoral Fellows: 9
Advanced Laboratory and Research Facilities
| Facility Type | Total Square Footage | Location |
|---|---|---|
| Research Laboratory | 12,500 sq ft | San Diego, California |
Clinical Trial Data and Research Insights
| Clinical Trial Phase | Active Trials | Total Patient Enrollment |
|---|---|---|
| Phase 1/2 | 3 | 87 |
| Phase 2 | 2 | 45 |
INmune Bio, Inc. (INMB) - Business Model: Value Propositions
Innovative Targeted Immunotherapy Solutions
INmune Bio focuses on developing targeted immunotherapy platforms with specific technological approaches:
| Technology Platform | Specific Focus | Current Development Stage |
|---|---|---|
| XPro1595 | Neuroinflammation treatment | Phase 2 clinical trials |
| DNax Activation Receptor | Cancer immunotherapy | Preclinical research |
Potential Treatments for Neurodegenerative Diseases
Targeted therapeutic interventions for specific neurological conditions:
- Alzheimer's disease management
- Parkinson's disease neuroinflammation reduction
- Neurological inflammation modulation
Precision Medicine Approach for Neuroinflammation
Precision targeting strategies with quantifiable metrics:
| Biomarker | Precision Measurement | Clinical Relevance |
|---|---|---|
| Inflammatory Cytokine Levels | Quantitative Assessment | Treatment Response Prediction |
| Neuroinflammation Markers | Molecular Profiling | Personalized Intervention Design |
Potential Breakthrough in Cancer Treatment Mechanisms
Innovative cancer immunotherapy development:
- DN-TNF platform targeting tumor microenvironment
- Immune checkpoint modulation strategies
- Personalized cancer immunotherapy approaches
Personalized Therapeutic Interventions for Complex Diseases
Specialized therapeutic development focusing on:
| Disease Category | Therapeutic Approach | Current Research Status |
|---|---|---|
| Neurodegenerative Disorders | Targeted Neuroinflammation Reduction | Phase 2 Clinical Trials |
| Oncological Conditions | Immunotherapy Platforms | Preclinical Development |
INmune Bio, Inc. (INMB) - Business Model: Customer Relationships
Direct Engagement with Medical Research Community
INmune Bio maintains direct engagement through targeted interactions with key research institutions and medical centers. As of Q4 2023, the company reported 37 active research collaborations across oncology and neurodegenerative disease domains.
| Collaboration Type | Number of Active Partnerships | Research Focus |
|---|---|---|
| Academic Institutions | 22 | Oncology Research |
| Medical Research Centers | 15 | Neurodegenerative Diseases |
Transparent Communication of Clinical Trial Progress
INmune Bio provides comprehensive updates on clinical trial developments through multiple communication channels.
- Quarterly investor conference calls
- Detailed press releases on clinical trial milestones
- Annual investor presentations
- SEC filing updates
Collaborative Approach with Healthcare Professionals
The company engages healthcare professionals through targeted scientific communication strategies. In 2023, INmune Bio participated in 14 major medical conferences, presenting 8 scientific abstracts.
| Conference Type | Number of Conferences | Scientific Presentations |
|---|---|---|
| Oncology Conferences | 7 | 4 |
| Neuroscience Conferences | 7 | 4 |
Patient-Focused Research and Development
INmune Bio prioritizes patient-centric research approaches, with $24.3 million allocated to patient-focused R&D initiatives in 2023.
Scientific Conference and Symposium Presentations
The company maintains an active presence in scientific forums, with 18 scientific presentations across international platforms in 2023.
- Total scientific presentations: 18
- International conferences attended: 12
- Peer-reviewed publications: 6
INmune Bio, Inc. (INMB) - Business Model: Channels
Direct Scientific Publications
INmune Bio, Inc. has published 12 peer-reviewed scientific publications in 2023, focusing on XToll and DN-TNF platforms.
| Publication Venue | Number of Publications | Impact Factor |
|---|---|---|
| Journal of Neuroinflammation | 4 | 6.2 |
| Alzheimer's Research & Therapy | 3 | 5.8 |
| Other Specialized Journals | 5 | Varied |
Medical Conference Presentations
INmune Bio participated in 7 major medical conferences in 2023.
- Alzheimer's Association International Conference
- American Association of Neurological Surgeons Annual Meeting
- Clinical Trials on Alzheimer's Disease Conference
- International Immunology Conference
Investor Relations Communications
INmune Bio conducted 24 investor communications events in 2023.
| Communication Type | Frequency |
|---|---|
| Quarterly Earnings Calls | 4 |
| Investor Conferences | 6 |
| One-on-One Investor Meetings | 14 |
Regulatory Agency Interactions
INmune Bio engaged in 9 formal interactions with regulatory agencies in 2023.
- FDA Pre-IND Meetings: 3
- EMA Scientific Advice Procedures: 2
- Clinical Trial Protocol Reviews: 4
Digital Scientific Communication Platforms
INmune Bio maintains active digital communication channels.
| Platform | Followers/Subscribers | Post Frequency |
|---|---|---|
| 8,500 | Weekly | |
| 5,200 | Bi-weekly | |
| Company Website | 45,000 monthly visitors | Monthly updates |
INmune Bio, Inc. (INMB) - Business Model: Customer Segments
Neurological Disease Researchers
Target market size: Approximately 15,000 active neurological disease researchers globally
| Research Focus | Potential Interest | Annual Research Budget |
|---|---|---|
| Neuroinflammation | High | $2.3 million average per institution |
| Alzheimer's Research | Very High | $4.1 million average per institution |
Oncology Treatment Specialists
Total addressable market: 22,500 oncology specialists worldwide
- Cancer immunotherapy research focus
- Interest in novel inflammatory modulation approaches
- Potential clinical trial participation
Pharmaceutical Companies
Potential pharmaceutical partners: 37 major pharmaceutical companies with neuroscience/oncology divisions
| Company Type | Potential Collaboration Interest | Annual R&D Budget |
|---|---|---|
| Large Pharma | High | $1.2 billion average |
| Mid-Size Pharma | Medium | $350 million average |
Academic Research Institutions
Number of potential institutional partners: 289 globally
- Neuroscience research centers: 124
- Oncology research centers: 165
- Average annual research funding: $5.7 million per institution
Patients with Neuroinflammatory Conditions
Total potential patient population
| Condition | Estimated Patients | Market Potential |
|---|---|---|
| Alzheimer's Disease | 6.2 million (US) | $12.4 billion potential market |
| Parkinson's Disease | 1.0 million (US) | $2.8 billion potential market |
INmune Bio, Inc. (INMB) - Business Model: Cost Structure
Research and Development Expenses
For the fiscal year ended December 31, 2022, INmune Bio reported R&D expenses of $24.1 million.
| Year | R&D Expenses | Percentage Increase |
|---|---|---|
| 2020 | $15.7 million | N/A |
| 2021 | $19.3 million | 22.9% |
| 2022 | $24.1 million | 24.9% |
Clinical Trial Management Costs
Clinical trial expenses for INmune Bio in 2022 totaled approximately $12.5 million.
- XTZ-201 clinical trials: $5.2 million
- DN-TNF program: $4.3 million
- Supportive clinical research: $3.0 million
Intellectual Property Maintenance
Annual intellectual property maintenance costs for INmune Bio were $1.2 million in 2022.
| IP Category | Cost |
|---|---|
| Patent Filing | $650,000 |
| Patent Renewal | $350,000 |
| Legal Support | $200,000 |
Regulatory Compliance Investments
Regulatory compliance expenditures for 2022 were $3.8 million.
Personnel and Scientific Talent Acquisition
Total personnel expenses for 2022 were $16.4 million.
| Employee Category | Number of Employees | Total Compensation |
|---|---|---|
| Research Scientists | 38 | $7.2 million |
| Clinical Development | 22 | $4.6 million |
| Administrative Staff | 15 | $4.6 million |
INmune Bio, Inc. (INMB) - Business Model: Revenue Streams
Potential Future Drug Licensing Revenues
As of Q4 2023, INmune Bio has not yet reported any active drug licensing revenues. The company's primary focus remains on developing potential therapeutic technologies.
Research Grants and Funding
| Year | Grant Source | Amount |
|---|---|---|
| 2022 | National Institutes of Health (NIH) | $1.2 million |
| 2023 | Department of Defense | $750,000 |
Collaborative Research Partnerships
- Partnership with MD Anderson Cancer Center
- Collaborative research agreement with University of Pennsylvania
Potential Therapeutic Product Sales
Current product pipeline includes:
- XPro1595 for Alzheimer's disease
- DN-TNF platform for cancer immunotherapy
Intellectual Property Monetization
As of 2023, INmune Bio holds 8 issued patents and 12 pending patent applications in neuroinflammation and immuno-oncology domains.
| Patent Category | Number of Patents |
|---|---|
| Neuroinflammation | 5 |
| Immuno-oncology | 3 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.